Equity Components [Axis]
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Temporary Equity [Member]
Class of Stock [Axis]
Series A (2011) [Member]
Series A (2013) [Member]
Series A (2013) [Member]
Series A (2015) [Member]
Series A (2016) [Member]
Series B (2016) [Member]
Related Party [Axis]
Technician Research And Development Foundation Limited [Member]
Range [Axis]
Minimum [Member]
Maximum [Member]
Title of Individual [Axis]
Board of Directors [Member]
Legal Entity [Axis]
Microbot Israel [Member]
Harel Gadot [Member]
Currency [Axis]
NIS [Member]
Exercise Price Range [Axis]
Exercise Price One [Member]
Exercise Price Two [Member]
Type of Arrangement and Non-arrangement Transactions [Axis]
Officer Lease Agreement [Member]
Purchaser [Member]
Preferred A Shares [Member]
Securities Purchase Agreement [Member]
Investor [Member]
Series A Convertible Preferred Stock [Member]
Alpha Capital [Member]
Advisors [Member]
Award Type [Axis]
Restricted Stock [Member]
Warrant [Member]
Hezi Himelfarb [Member]
Exercise Price Three [Member]
Car Lease Agreements [Member]
Income Statement Location [Axis]
General and Administrative Expense [Member]
Employees [Member]
Employees and Consultant [Member]
Consultant [Member]
Exercise Price Four [Member]
Exercise Price Five [Member]
CardioSert Ltd [Member]
Directors [Member]
Measurement Input Type [Axis]
Measurement Input Price Volatility [Member]
Measurement Input Risk Free Interest Rate [Member]
Measurement Input, Exercise Price [Member]
Measurement Input, Price Volatility [Member]
Measurement Input, Risk Free Interest Rate [Member]
Measurement Input, Expected Dividend Rate [Member]
Measurement Input, Expected Term [Member]
Research and Development Expense [Member]
Before Reverse Split [Member]
Mr. Simon Sharon [Member]
Exercise Price Six [Member]
Treasury Shares [Member]
Award Date [Axis]
First Quarter of 2019 [Member]
Property, Plant and Equipment, Type [Axis]
Research Equipment and Software [Member]
Furniture and Office Equipment [Member]
Leasehold Improvements [Member]
Research and Development Arrangement, Contract to Perform for Others, Type [Axis]
Israeli Innovation Authority [Member]
2013 Through December 31, 2018 [Member]
Contract Research Agreements [Member]
Second Phase [Member]
Interested and Related Parties [Member]
Income Tax Authority, Name [Axis]
Israel Tax Authority [Member]
Tax Period [Axis]
2016 [Member]
2017 [Member]
From 2018 [Member]
US Tax Authority [Member]
Tax Act [Member]
From January 1, 2018 [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Pre-Funded Warrant [Member]
Non-employee Directors [Member]
Former Executive [Member]
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Filer Category
Entity Small Business Flag
Entity Emerging Growth Company
Entity Ex Transition Period
Entity Shell Company
Entity Public Float
Entity Common Stock, Shares Outstanding
Trading Symbol
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement of Financial Position [Abstract]
ASSETS
Current assets:
Cash and cash equivalents
Restricted cash
Other current assets
Total current assets
Fixed assets, net
Total assets
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Trade payables
Accrued liabilities
Other accrued liabilities
Total current liabilities
Long-term liabilities:
Derivative warrant liability
Total Long-term liabilities
Total liabilities
Commitments and contingencies
Temporary equity:
Common stock of $0.01 par value; issued and outstanding: 0 and 721,107 shares as of December 31, 2018 and 2017
Shareholders' equity:
Preferred stock of $0.01 par value; Authorized: 1,000,000 shares as of December 31, 2018 and 2017; issued and outstanding: 0 and 4,001 shares as of December 31, 2018 and 2017, respectively
Common stock of $0.01 par value; Authorized: 220,000,000 as of December 31, 2018 and 2017; issued and outstanding (**): 3,012,343 and 2,013,193 shares as of December 31, 2018, and December 31, 2017, respectively
Additional paid-in capital
Treasury shares
Accumulated deficit
Total shareholders' equity
Total liabilities and shareholders' equity
Temporary equity, par value
Temporary equity, shares issued
Temporary equity, shares outstanding
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Reverse stock split
Income Statement [Abstract]
Research and development expenses, net
General and administrative expenses
Operating loss
Financing (income) expenses, net
Net loss and comprehensive loss
Net loss per share, basic and diluted
Weighted-average number of common shares outstanding, basic and diluted (*)
Statement [Table]
Statement [Line Items]
Balance
Balance, shares
Issuance of common stock
Issuance of common stock, shares
Share-based compensation
Share-based compensation, shares
Exercise of options
Exercise of options, shares
Cashless exercise of warrants
Cashless exercise of warrants, shares
Extinguishment of convertible notes and issuance of preferred A shares
Extinguishment of convertible notes and issuance of preferred A shares, shares
Conversion of preferred A shares to common stock
Conversion of preferred A shares to common stock, shares
Common shares classified out of temporary equity
Shares issued as consideration-vendor
Shares issued as consideration-vendor, shares
Rescission of share purchase agreement
Net loss
Balance
Balance, shares
Statement of Stockholders' Equity [Abstract]
Temporary equity
Statement of Cash Flows [Abstract]
OPERATING ACTIVITIES
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Interest and amortization of discount on convertible notes
Financing loss on debt extinguishment
Changes in fair value of derivative warrant liability
Shares issued as consideration-vendor
Share-based compensation expense
Changes in assets and liabilities:
Other receivables
Other payables and accrued liabilities
Net cash used in operating activities
INVESTMENT ACTIVITIES
Purchase of property and equipment
Net cash used in investing activities
FINANCING ACTIVITIES
Inflows in connection with current assets and liabilities acquired in reverse recapitalization, net
Deferred financing fees
Issuance of common stock, net of issuance costs
Net cash (used in) provided by financing activities
(Decrease) increase in cash and cash equivalents
Cash and cash equivalents and restricted cash at the beginning of the year
Cash and cash equivalents and restricted cash at the end of the year
Supplemental disclosure of cash flow information:
Non-cash financing transactions:
Cashless exercise of warrants
Rescission of share purchase agreement
Conversion of Series A Convertible Preferred Stock into common stock
Extinguishment of convertible notes in exchange for Series A Convertible Preferred Stock
Financing fees included in other payables and accrued liabilities
Temporary equity classified to permanent equity
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General
Accounting Policies [Abstract]
Summary of Significant Accounting Policies
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Current Assets
Property, Plant and Equipment [Abstract]
Fixed Assets, Net
Payables and Accruals [Abstract]
Accrued Liabilities
Debt Disclosure [Abstract]
Convertible Loan from Shareholders
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Warrant Liabilities
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Equity [Abstract]
Share Capital
Earnings Per Share [Abstract]
Basic and Diluted Net Loss Per Share
Research and Development [Abstract]
Research and Development Expenses, Net
General and Administrative Expense [Abstract]
General and Administrative Expenses
Other Income and Expenses [Abstract]
Finance Expenses, Net
Related Party Transactions [Abstract]
Transactions and Balances With Interested and Related Parties
Income Tax Disclosure [Abstract]
Taxes on Income
Subsequent Events [Abstract]
Subsequent Events
Basis of Presentation
Financial Statement in U.S. Dollars
Cash and Cash Equivalents
Fair Value of Financial Instruments
Fixed Assets
Liabilities Due to Termination of Employment Agreements
Basic and Diluted Net Loss Per Share
Research and Development Expenses, Net
Share-Based Compensation
Reclassification
Income Taxes
Recent Accounting Standards
Estimated Useful Lives of Property and Equipment
Schedule of Other Current Assets
Summary of Fixed Assets, Net
Summary of Accrued Liabilities
Schedule of Outstanding Warrants Liabilities
Schedule of Valuation of Derivative Warrant Liabilities
Schedule of Fair Value Assumption
Schedule of Liabilities Measured on a Recurring Basis
Summary of Stock Option Activity
Schedule of Stock Options Outstanding
Schedule of Stock Options Valuation Assumptions
Schedule of Basic and Diluted Net Loss Per Share
Schedule of Research and Development Expenses
Schedule of General and Administrative Expenses
Summary of Finance Expenses, Net
Schedule of Related Party Transaction and Balances
Schedule of Deferred Tax Assets
Schedule of Statutory Corporate Tax Rate and Effective Income Tax Rate
Cash and cash equivalent
Proceeds from consideration the sale
Reverse stock split, shares
Property, Plant and Equipment [Table]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life
Amounts due from government institutions
Deferred costs related to issuance of common shares (see Note 16)
Prepaid expenses and others
Total Other current assets
Cost
Accumulated Depreciation
Fixed Assets, net
Employee-related liabilities
Amounts due to certain government institution
Other current liabilities
Total Accrued Liabilities
Rights to acquire shares of common stock
Designated preferred stock
Rights to acquire shares of common stock were cancelled
Common stock shares issued and outstanding reduced during the period
Number of shares issued during period
Loan bears interest rate
Debt instrument face amount
Debt maturity date
Loss on extinguishment of convertible note
Cashless exercise warrants
Warrant calculation description
Fair value assumption rate
Number of Warrant Outstanding, shares
Warrant Exercise Price, Per Share
Warrant Exercisable
Number of Warrant Exercisable, Period
Estimated fair value of warrant liability
Balances at December 31, 2017
Exercised
Expired
Changes in fair value
Balances at December 31, 2018
Share price
Fair value assumption, price
Fair value assumption, percentage
Fair value assumption expected life of up to (years)
Beginning balance
Revaluation of warrants
Exercise warrants
Ending balance
Total grants obtained
Royalties payable as percentage of future sales
Lease term
Monthly lease payment
Contract expected costs
Compensation commitments
Purchase price of Plaintiffs
Loss contingency, damages sought
Short-term liability
Initial payment
Number of common shares acquired
Number of common shares acquired, value
Investments
Buy back amount per patent
Monthly consultation fee
Conversion of stock into shares
Cashless exercise warrants
Authorized capital stock
Ordinary shares, par value
Number of common stock shares sold during the period
Common stock price per share
Proceeds from issuance of shares
Placement agent fee
Number of stock options granted
Number of stock option granted as adjustment of reflect merger
Weighted-average exercise price per share, granted
Stock option merger retroactively adjusted exercise price per share
Stock-based employee compensation
Stock option vested term
Number of option exercised
Number of shares issued for services
Number of shares issued for services, value
Number of common shares issued for acquisition
Repurchase of common stock
Fair market value percentage
Temporary equity value
Number of Stock Options Outstanding, Outstanding at Beginning Balance
Number of Stock Options Outstanding, Granted
Number of Stock Options Outstanding, Exercised
Number of Stock Options Outstanding, Cancelled
Number of Stock Options Outstanding, Outstanding at Ending Balance
Number of Stock Options Outstanding, Vested and expected-to-vest at end of period
Weighted Average Exercise Price, Outstanding at Beginning Balance
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Outstanding at Ending Balance
Weighted Average Exercise Price, Vested and expected-to-vest at end of period
Aggregate intrinsic value, Stock Options Outstanding at Beginning period
Aggregate intrinsic value, Stock Options Outstanding at End period
Aggregate intrinsic value, Vested and expected-to-vest at end of period
Exercise price
Stock options outstanding
Weighted average remaining contractual life
Stock options exercisable
Expected volatility
Risk-free interest
Dividend yield
Expected life of up to (years)
Net loss attributable to shareholders of the Company
Net loss attributable to shareholders of preferred shares
Net loss used in the calculation of basic net loss per share
Net loss per share
Weighted average number of common shares
Payroll and related expenses
Share-based compensation
Materials
Patents
Office and maintenance expenses
Rent
Professional services
Other
Less: Grants received from IIA & EC
Research and development expense
Share-based compensation
Travel
Marketing expenses
Public and investor relations
Insurance
Government fees
Other
General and administrative expenses
Bank fees and interest
Change in fair value of derivative warrant liability
Exchange rate differences
Revaluation and interest on convertible loans
Financial expenses, net
Directors fees and insurance
Subcontracted work and consulting
Total
Other accounts payable
Total
Corporate income tax rate
Reduced federal tax rate
Net operating losses carried forward
Operating loss carryforwards, expiration
Net operating loss carry-forward
Total deferred tax assets
Valuation allowance
Net deferred tax assets
Net loss as reported in the statements of operations
Statutory tax rate
Income Tax under statutory tax rate
Change in valuation allowance
Actual income tax
Number of common stock sale
Sale of stock price per share
Warrant to purchase for common stock
Warrant price per share
Proceeds from issuance and sale of stock
Number of common stock for granted
Advisors [Member]
Alpha Capital [Member]
Before Reverse Split [Member]
Board of Directors [Member]
Buy back amount per patent.
Car Lease Agreements [Member]
CardioSert Ltd [Member]
Cashless exercise of warrants.
Cashless exercise warrants.
Cashless exercise warrants.
Common stock shares issued and outstanding reduced during the period.
Compensation commitments.
Consultant [Member]
Conversion of convertible notes into preferred A shares.
Derivative warrant liabilities.
Exercised.
Expired.
Designated preferred stock.
Directors [Member]
Employees and Consultant [Member]
Employees [Member]
Exercise Price Five [Member]
Exercise Price Four [Member]
Exercise Price One [Member]
Exercise Price Six [Member]
Exercise Price Three [Member]
Exercise Price Two [Member]
Exercise warrants.
Extinguishment of convertible notes and issuance of preferred shares.
Extinguishment of convertible notes and issuance of preferred shares, shares.
Extinguishment of convertible notes in exchange for preferred A shares.
Fair market value percentage.
Fair value assumption expected life of up to (years).
Fair value assumption, percentage.
Fair value assumption, price.
Fair value assumption rate.
First Quarter of 2019 [Member]
Former Executive [Member]
Furniture And Office Equipment [Member]
General and administrative expenses [Text Block].
Hazel Gadot [Member]
Hezi Himelfarb [Member]
Israeli Innovation Authority [Member]
Lease term.
Microbot Israel [Member]
Mr. Simon Sharon [Member]
Net Sales Royalty Percentage
Number Of Stock Option Granted As Adjustment Of Reflect Merger.
Number of Warrant Exercisable, Period.
Officer Lease Agreement [Member].
Placement agent fee.
Preferred Stock [Member]
Purchaser [Member].
Rescission of share purchase agreement.
Research Equipment and Software [Member]
Revaluation of warrants.
Rights to acquire shares of common stock.
Rights to acquire shares of common stock were cancelled.
Schedule of Property and Equipment Useful Lives [Table Text Block]
Schedule of General and Administrative Expense [Table Text Block]
Securities Purchase Agreement [Member]
Series A Convertible Preferred Shares [Member]
Series A (2011) [Member]
Series A (2015) [Member]
Series A (2016) [Member]
Series A (2013) [Member]
Series A (2013) One [Member]
Series B (2016) [Member]
Shares issued as consideration-vendor.
Stock Issued During Period Shares Cashless Exercise Of Warrants.
Number of share options (or share units) exercised during the current period.
Stock Issued During Period Value Cashless Exercise Of Warrants.
Stock option merger retroactively adjusted exercise price per share.
Technician Research And Development Foundation Limited [Member]
Temporary Equity [Member]
2017 Equity Incentive Plan [Member]
2013 Through September 30, 2018 [Member]
Vice President of R&D [Member]
Warrant calculation description.
Warrant Exercisable.
Derivative warrant liabilities.
2013 Through December 31, 2018 [Member]
Contract expected costs.
Contract Research Agreements [Member]
Second Phase [Member]
Amount of general and administrative expense related to public and investor relation.
The amount of expense provided in the period for government service fees.
Interested and Related Parties [Member]
2016 [Member]
2017 [Member]
From 2018 [Member]
US Tax Authority [Member]
Tax Act [Member]
From January 1, 2018 [Member]
Operating Loss Carryforwards, Expiration.
Finance Expenses [Member]
Pre-Funded Warrant [Member]
Non-employee Directors [Member]
Office and maintenance expenses.
Revenues from grants.
Amounts due to certain government institution.
Inflows in connection with current assets and liabilities acquired in reverse recapitalization, net.
Financing fees included in other payables and accrued liabilities.
Temporary equity classified to permanent equity.
SeriesATwoThousandAndThirteenOneMember
Assets, Current
Assets
Liabilities, Current
Liabilities, Noncurrent
Liabilities
Stockholders' Equity Attributable to Parent
Liabilities and Equity
Operating Income (Loss)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Shares, Outstanding
Gain (Loss) on Extinguishment of Debt
SharesIssuedAsConsiderationVendor
Increase (Decrease) in Other Receivables
Net Cash Provided by (Used in) Operating Activities
Payments to Acquire Property, Plant, and Equipment
Net Cash Provided by (Used in) Investing Activities
Payments of Financing Costs
Net Cash Provided by (Used in) Financing Activities
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
CashlessExerciseOfWarrants
Earnings Per Share, Policy [Policy Text Block]
Research and Development Expense, Policy [Policy Text Block]
DerivativeWarrantLiabilitiesBeginningBalance
DerivativeWarrantLiabilitiesEndingBalance
CashlessExerciseShares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
RevenuesFromGrants
Other General and Administrative Expense
Foreign Currency Transaction Gain (Loss), before Tax
Costs and Expenses, Related Party
Due to Related Parties
Deferred Tax Assets, Valuation Allowance
Deferred Tax Assets, Net of Valuation Allowance